Several US hospitals using HCQ in treatment of COVID-19 patients: Report

Image
Press Trust of India Washington
Last Updated : May 02 2020 | 11:33 AM IST

Several hospitals in the US are using the antimalarial drug hydroxychloroquine as the first-line of therapy for COVID-19 positive patients, a medical publication has reported.

MDedge on Friday reported that hydroxychloroquine (HCQ) is currently the first-line therapy and Tocilizumab the second-line medication for people hospitalised with polymerase chain reaction-confirmed COVID-19 infection in the Yale New Haven Health System, which operates hospitals across Connecticut, one of the hotspots in the US.

Hydroxychloroquine is one of the oldest and best-known anti-malarial drugs. US President Donald Trump has called hydroxychloroquine a "game-changer" drug in the fight against COVID-19.

At Trump's request, India last month allowed the export of 50 million HCQ tablets to treat COVID-19 patients in America, the worst-hit country by the pandemic.

Hydroxychloroquine is first-line at Yale because in-vitro data shows potent inhibition of the virus and possible clinical benefit, which is about as good as evidence gets at the moment, Indian-American cardiologist Nihar Desai told the medical publication.

"It's cheap, it's been used for decades, and people are relatively comfortable with it," he added.

"We are trying to do the best we can. One hopes we never have to go through anything like this (coronavirus pandemic) again," Desai told MDedge.

His home institution, Yale New Haven Hospital, is almost half full with COVID-19 patients, at more than 400, the report said.

On Friday, US Food and Drug Administration gave emergency use authorization (EUA) for the use of investigational anti-viral Remdesivir for the treatment of COVID-19 patients.

HCQ was the first drug to receive EAU from FDA for the treatment of COVID-19 patients.

The vaccine has reportedly cured patients in New York and several other places.

Reports indicate that the malaria drug has been effective during the initial phases of a person being infected by coronavirus but poses a danger to those having heart ailments.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 02 2020 | 11:33 AM IST

Next Story